Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Rigel ( (RIGL) ) has issued an announcement.
On May 22, 2025, Rigel Pharmaceuticals, Inc. held its 2025 Annual Meeting of Stockholders, where stockholders approved an amendment to the 2018 Equity Incentive Plan, adding 700,000 shares for issuance. The plan became effective immediately upon approval. Additionally, stockholders elected directors to serve until the 2028 Annual Meeting, approved executive compensation, and ratified Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2023.
The most recent analyst rating on (RIGL) stock is a Buy with a $150.00 price target. To see the full list of analyst forecasts on Rigel stock, see the RIGL Stock Forecast page.
Spark’s Take on RIGL Stock
According to Spark, TipRanks’ AI Analyst, RIGL is a Outperform.
Rigel Pharmaceuticals shows a strong financial trajectory with impressive revenue growth and profitability. The high financial performance score is supported by robust cash flows and efficient cost management, though high leverage poses a risk. Technical indicators suggest moderate bullish momentum, while the low P/E ratio indicates potential undervaluation. The positive earnings call further bolsters confidence in Rigel’s future prospects. Overall, Rigel is on a promising path, but investors should remain cautious of leverage-related risks.
To see Spark’s full report on RIGL stock, click here.
More about Rigel
Rigel Pharmaceuticals, Inc. operates in the biotechnology industry, focusing on the development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases.
Average Trading Volume: 233,143
Technical Sentiment Signal: Buy
Current Market Cap: $352.6M
Find detailed analytics on RIGL stock on TipRanks’ Stock Analysis page.